Development of a Microfluidic Vascularized Osteochondral Model as a Drug Testing Platform for Osteoarthritis
Advanced Healthcare Materials · 2024-12 · 13 (31)
DOI: 10.1002/adhm.202402350 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 06.10.2024. Verfasst von Shima Salehi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cell and Tissue Engineering Laboratory, IRCCS Istituto Ortopedico Galeazzi, Via Belgioioso 173, Milan, 20157, Italy. Hauptthemen laut MEDLINE: Osteoarthritis, Chondrocytes. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Osteoarthritis (OA) is a degenerative joint disease characterized by changes in cartilage and subchondral bone. To date, there are no available drugs that can counteract the progression of OA, partly due to the inadequacy of current models to recapitulate the relevant cellular complexity. In this study, an osteochondral microfluidic model is developed using human primary cells to mimic an OA‐like microenvironment and this study validates it as a drug testing platform. In the model, the cartilage compartment is created by embedding articular chondrocytes in fibrin hydrogel while the bone compartment is obtained by embedding osteoblasts, osteoclasts, endothelial cells, and mesenchymal stem cells in a fibrin hydrogel enriched with calcium phosphate nanoparticles. After developing and characterizing the model, Interleukin‐1 β is applied to induce OA‐like conditions. Subsequently, the model potential is evaluated as a drug testing platform by assessing the effect of two anti‐inflammatory drugs (Interleukin‐1 Receptor antagonist and Celecoxib) on the regulation of inflammation‐ and matrix degradation‐related markers. The model responded to inflammation and demonstrated differences in drug efficacy. Finally, it compares the behavior of the “Cartilage” and “Cartilage+Bone” models, emphasizing the necessity of incorporating both cartilage and bone compartments to capture the complex pathophysiology of OA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cell and Tissue Engineering Laboratory, IRCCS Istituto Ortopedico Galeazzi, Via Belgioioso 173, Milan, 20157, Italy.
- Department of Electronics, Information and Bioengineering, Politecnico di Milano, Via Ponzio 34/5, Milan, 20133, Italy.
- Regenerative Medicine Technologies Lab, Laboratories for Translational Research (LRT), Ente Ospedaliero Cantonale (EOC), Via Chiesa 5, Bellinzona, 6500, Switzerland.
- Service of Orthopaedics and Traumatology, Department of Surgery, EOC, Via Tesserete 46, Lugano, 6900, Switzerland.
- Euler Institute, Faculty of Biomedical Sciences, Università della Svizzera Italiana (USI), Via Buffi 13, Lugano, 6900, Switzerland.
ORCID-Profile: Shima Salehi, Stefania Brambilla, Marco Rasponi, Silvia Lopa, Matteo Moretti
Zitieren
APA
Salehi, S., Brambilla, S., Rasponi, M., Lopa, S., & Moretti, M. (2024). Development of a Microfluidic Vascularized Osteochondral Model as a Drug Testing Platform for Osteoarthritis. Advanced Healthcare Materials, 13(31). https://doi.org/10.1002/adhm.202402350
Vancouver
Salehi S, Brambilla S, Rasponi M, Lopa S, Moretti M. Development of a Microfluidic Vascularized Osteochondral Model as a Drug Testing Platform for Osteoarthritis. Advanced Healthcare Materials. 2024;13(31). doi:10.1002/adhm.202402350
BibTeX
@article{Salehi2024,
author = {Salehi, Shima and Brambilla, Stefania and Rasponi, Marco and Lopa, Silvia and Moretti, Matteo},
title = {Development of a Microfluidic Vascularized Osteochondral Model as a Drug Testing Platform for Osteoarthritis},
journal = {Advanced Healthcare Materials},
year = {2024},
volume = {13},
number = {31},
doi = {10.1002/adhm.202402350}
}
EUVIMED